08Feb 2022
February 08, 2022 - Holy Stone Healthcare Co., Ltd. (4194.TW) completed the clinical study report for the Phase 1 clinical study of CA102N which is a new anti-cancer drug for the treatment of colorectal cancer.
read more
24Dec 2021
US FDA approved on December 21, 2021, Holy Stone Healthcare’s application for compassionate use of CA102N in phase I clinical trials.
read more
24Nov 2021
Holy Stone Healthcare submitted an application to the US FDA for compassionate use of its new drug, CA102N, for the treatment of colorectal cancer, in phase I clinical trials.
read more

Vision & Mission

We are committed to developing lifesaving therapeutics and targeted delivery technologies to improve the quality of life of patients worldwide. Our mission is to create innovative therapeutic products based on hyaluronic acid using our know-how and experience to address unmet clinical needs with superior tolerability and efficacy.


We are focused on development of new drugs and medical devices, especially hyaluronic acid related therapeutic products.